Abstract
The plasma levels of three lysosomal enzymes, β-D-N-acetylglucosaminidase, β-D-glucuronidase, and α-L-fucosidase, were fluorimetrically determined in seven insulin-dependent diabetic patients one day before, one day after, and during a two-day treatment with the artificial pancreas, at 4 to 5 h intervals. A statistically significant decrease of the plasma level of each enzymes was observed during artificial pancreas treatment. The extent of decrease was 30 to 35% for β-N-acetylglucosaminidase, 35 to 40% for β-D-glucuronidase, and 20 to 25% for α-L-fucosidase. The decrease occurred earlier (at the first day of treatment) for β-D-N-acetylglucosaminidase, and later (at the second day of treatment, and lasting to the first day after treatment) for the other two enzymes. These results suggest a direct connection between the lysosomal apparatus and insulin-controlled metabolic pathways, and a potential role for lysosomal enzymes as indicators of the metabolic compensation in diabetes.
| Original language | English |
|---|---|
| Pages (from-to) | 423-427 |
| Number of pages | 5 |
| Journal | Clinical Biochemistry |
| Volume | 20 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 1987 |
Fingerprint
Keywords
- artificial pancreas
- diabetes
- lysosomal enzymes
- plasma clinical enzymology
ASJC Scopus subject areas
- Clinical Biochemistry
Cite this
Behaviour of some lysosomal enzymes in the plasma of insulin dependent diabetic patients during artificial pancreas treatment. / Burlina, A. B.; Goi, G.; Fabi, A.; Lombardo, A.; Gaburro, D.; Tettamanti, G.
In: Clinical Biochemistry, Vol. 20, No. 6, 1987, p. 423-427.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Behaviour of some lysosomal enzymes in the plasma of insulin dependent diabetic patients during artificial pancreas treatment
AU - Burlina, A. B.
AU - Goi, G.
AU - Fabi, A.
AU - Lombardo, A.
AU - Gaburro, D.
AU - Tettamanti, G.
PY - 1987
Y1 - 1987
N2 - The plasma levels of three lysosomal enzymes, β-D-N-acetylglucosaminidase, β-D-glucuronidase, and α-L-fucosidase, were fluorimetrically determined in seven insulin-dependent diabetic patients one day before, one day after, and during a two-day treatment with the artificial pancreas, at 4 to 5 h intervals. A statistically significant decrease of the plasma level of each enzymes was observed during artificial pancreas treatment. The extent of decrease was 30 to 35% for β-N-acetylglucosaminidase, 35 to 40% for β-D-glucuronidase, and 20 to 25% for α-L-fucosidase. The decrease occurred earlier (at the first day of treatment) for β-D-N-acetylglucosaminidase, and later (at the second day of treatment, and lasting to the first day after treatment) for the other two enzymes. These results suggest a direct connection between the lysosomal apparatus and insulin-controlled metabolic pathways, and a potential role for lysosomal enzymes as indicators of the metabolic compensation in diabetes.
AB - The plasma levels of three lysosomal enzymes, β-D-N-acetylglucosaminidase, β-D-glucuronidase, and α-L-fucosidase, were fluorimetrically determined in seven insulin-dependent diabetic patients one day before, one day after, and during a two-day treatment with the artificial pancreas, at 4 to 5 h intervals. A statistically significant decrease of the plasma level of each enzymes was observed during artificial pancreas treatment. The extent of decrease was 30 to 35% for β-N-acetylglucosaminidase, 35 to 40% for β-D-glucuronidase, and 20 to 25% for α-L-fucosidase. The decrease occurred earlier (at the first day of treatment) for β-D-N-acetylglucosaminidase, and later (at the second day of treatment, and lasting to the first day after treatment) for the other two enzymes. These results suggest a direct connection between the lysosomal apparatus and insulin-controlled metabolic pathways, and a potential role for lysosomal enzymes as indicators of the metabolic compensation in diabetes.
KW - artificial pancreas
KW - diabetes
KW - lysosomal enzymes
KW - plasma clinical enzymology
UR - http://www.scopus.com/inward/record.url?scp=0023555463&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023555463&partnerID=8YFLogxK
U2 - 10.1016/0009-9120(87)90009-9
DO - 10.1016/0009-9120(87)90009-9
M3 - Article
C2 - 3436039
AN - SCOPUS:0023555463
VL - 20
SP - 423
EP - 427
JO - Clinical Biochemistry
JF - Clinical Biochemistry
SN - 0009-9120
IS - 6
ER -